Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Time spent above, not below, the target glucose range was associated with mortality in a study of adults with type 2 diabetes ...

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Texas residents who were exposed to greater levels of toxic metals were found to develop markers for type 2 diabetes earlier.

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the ...

An interdisciplinary research team, including the Faculty of Engineering and Li Ka Shing Faculty of Medicine at The ...

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

The FDA has cleared Senseonics and Ascensia Diabetes Care's Eversense 365 Glucose Monitoring System. This system is designed for Type 1 and Type 2 diabetics 18 and older and will be the first ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...